- Resmed sold its MatrixCare business to Frazier Healthcare Partners on July 1, 2026.
- Analysts are reviewing Resmed's divestiture and acquisition strategy, noting long-term benefits despite near-term EPS dilution.
- Analyst discusses market risks facing ResMed stock.
A committee has selected ResMed Inc. as an undervalued stock and Broadridge Financial Resources Inc. as a stock to study.
1 report, 1 independent
Updated Jul 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A committee has selected ResMed Inc. as an undervalued stock and Broadridge Financial Resources Inc. as a stock to study.